News

Successful Validation of Novel AmyloFlextm Modified Release Technology Platform: New Safer to Use Value Added Tablets AHMEDABAD, INDIA and LAVAL, QC / ACCESSWIRE / January 27, 2021 / Cadila Pharmaceuticals Limited ("Cadila") and Altus Formulation Inc. ("Altus") today...

Altus Formulation is an R&D focused pharmaceutical development company with a suite of proprietary drug delivery technologies and a rapidly growing portfolio of co-development and licensing agreements with a range of global partners. Altus is seeking a Head of...

MONTREAL, QC / ACCESSWIRE / March 5, 2018 / Recipharm, the contract development and manufacturing organisation (CDMO), has signed a licensing agreement with Altus Formulation Inc., a Canadian drug development company, to allow its customers to access new drug delivery...

Altus is pleased to present FLEXITABTM, an innovative and commercially validated technology platform providing novel, value added life-cycle management opportunities through Safer UseTM breakable, extended release (ER) tablets. Conventional ER tablets may ‘dose dump’...

Altus Formulation Inc. a Quebec based drug development company, leveraging its patented delivery technologies to develop novel Safer to UseTM formulations for its partners and their patients is pleased to announce the allowance of its first FLEXITABTM patent in Europe...